
bluebird bio agrees to acquisition due to “financial challenges”
bluebird bio has entered into a definitive agreement to be acquired by global investment firms Carlyle and SK Capital Partners in collaboration with a team of highly experienced biotech executives. The decision was made after a third and final denial by the Food & Drug Administration (FDA) of bluebird’s appeal… Read More














